EUVIMEDEUVIMED entdecken
ÄquivalenzstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access

Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia

Ritu Banerjee, Lauren Komarow, Yixuan Li, Donald Mau, Andrew Dodd, Holly Geres, Kerryl Greenwood-Quaintance, Amos Adler, Shrikala Baliga, Michal Chowers, George Chrysos, Olympia Zarkotou und 8 weitere

JAMA · 26.05.2026 · 335 (20) · 1762

DOI: 10.1001/jama.2026.5487 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift JAMA, erschienen am 26.05.2026. Verfasst von Ritu Banerjee und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteremia, Cross Infection, Gram-Negative Bacteria. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Novel blood culture diagnostics provide rapid antimicrobial susceptibility testing (AST) results for bacteria causing bloodstream infections (BSIs) but have unclear clinical impact.

Objective

To evaluate clinical outcomes of blood culture testing using a rapid AST method compared with standard AST in patients with BSIs caused by gram-negative bacilli in regions with high prevalence of antimicrobial resistance. Design, Setting, and Participants Open-label randomized clinical trial that enrolled participants from December 2023 to May 2025 (final follow-up, June 18, 2025) at 7 medical centers in Greece (n = 2), India (n = 1), Israel (n = 3), and Spain (n = 1). Hospitalized patients (adults and children) with BSIs caused by gram-negative bacilli were eligible. Statistical analysis was conducted from August 2025 to January 2026.

Intervention

Patients were randomized to undergo blood culture evaluation using rapid, phenotypic AST directly from positive blood cultures plus standard susceptibility testing (n = 413) vs standard susceptibility testing alone (n = 437). Local antimicrobial stewardship teams reviewed all patients and provided treatment recommendations. Main Outcomes and Measures The primary outcome was a desirability of outcome ranking (DOOR) at day 30, with 3 categories (alive without deleterious events, alive with deleterious events, and death). The difference between rapid and standard testing was summarized as the probability that the DOOR outcomes were more desirable in the rapid testing group. Superiority was concluded if the lower limit of the 95% CI exceeded 50%. Secondary outcomes included 30-day mortality, length of hospitalization, intensive care unit admission, acquisition of hospital-acquired infections, time to effective antibiotic therapy within 3 days, and time to antibiotic escalation or deescalation within 3 days.

Results

Of the 899 patients randomized, 850 were included in the primary outcome analysis (median [IQR] age, 72 [21] years; 43% female). The probability that DOOR outcomes were more favorable in the rapid testing group was 48.8% (95% CI, 45.3%-52.4%). Median time to effective antibiotic therapy was not different between the groups in the as-randomized population. Median time to antibiotic escalation or deescalation was faster in the rapid testing group by 14 hours (95% CI, 6-22) in the as-randomized population. There were no differences between the groups in other secondary outcomes. In the prespecified subgroup with carbapenem-resistant infections, median time to effective therapy was 9.5 hours in the rapid testing group vs 28 hours in the standard testing group (difference, −18 hours [95% CI, −42 to 6]). Conclusions and Relevance Among patients with gram-negative bacilli BSIs, rapid blood culture AST was not superior to standard testing by DOOR. When considered with other efficacy and safety outcomes, these findings may help inform the use of rapid susceptibility testing in clinical practice. Trial Registration ClinicalTrials.gov Identifier: NCT06174649

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsBacteremiaCross InfectionGram-Negative BacteriaGram-Negative Bacterial InfectionsAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntimicrobial StewardshipBlood CultureDrug Resistance, BacterialFollow-Up StudiesIntensive Care UnitsLength of StayMicrobial Sensitivity TestsRapid Diagnostic TestsTime Factors

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • The Biostatistics Center and Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Bethesda, Maryland.
  • Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Department of Microbiology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Banerjee, R., Komarow, L., Li, Y., Mau, D., Dodd, A., Geres, H., Greenwood-Quaintance, K., Adler, A., Baliga, S., Chowers, M., Chrysos, G., Zarkotou, O., Paul, M., Pournaras, S., Regueiro, D. S., Evans, S., Chambers, H., Fowler, V. G., Patel, R., & Antibacterial Resistance Leadership Group (2026). Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia. JAMA, 335(20), 1762. https://doi.org/10.1001/jama.2026.5487

Vancouver

Banerjee R, Komarow L, Li Y, Mau D, Dodd A, Geres H, et al. Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia. JAMA. 2026;335(20):1762. doi:10.1001/jama.2026.5487

BibTeX
@article{Banerjee2026,
  author = {Banerjee, Ritu and Komarow, Lauren and Li, Yixuan and Mau, Donald and Dodd, Andrew and Geres, Holly and Greenwood-Quaintance, Kerryl and Adler, Amos and Baliga, Shrikala and Chowers, Michal and Chrysos, George and Zarkotou, Olympia and Paul, Mical and Pournaras, Spyros and Regueiro, Dolores Sousa and Evans, Scott and Chambers, Henry and Fowler, Vance G and Patel, Robin and Antibacterial Resistance Leadership Group, Antibacterial Resistance Leadership Group},
  title = {Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {20},
  pages = {1762},
  doi = {10.1001/jama.2026.5487}
}
Kostenlos starten →